To view the PDF file, sign up for a MySharenet subscription.

ASPEN PHARMACARE HOLDINGS LIMITED - Final Completion of the Divestment of the European Thrombosis Business to Mylan/Viatris

Release Date: 01/07/2021 16:19
Code(s): APN     PDF:  
Wrap Text
Final Completion of the Divestment of the European Thrombosis Business to Mylan/Viatris

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa) (“Aspen Holdings”)
Registration number: 1985/002935/06
Share code: APN
ISIN: ZAE000066692
LEI: 635400ZYSN1IRD5QWQ94
and its subsidiaries (collectively “Aspen” or “the Group”)

FINAL COMPLETION OF THE DIVESTMENT OF THE EUROPEAN THROMBOSIS BUSINESS TO MYLAN/VIATRIS

Aspen is pleased to confirm that the divestment of the European Thrombosis Assets(1) (the “Assets”) by its
wholly owned subsidiary, Aspen Global Incorporated (“AGI”) to Mylan Ireland Limited (“Mylan/Viatris”) for a
total purchase consideration of EUR 641.9 million, plus the cost of the related inventory (the “Transaction”),
as announced on 8 September 2020, has now been completed in full.

The disposal of the Assets comprised the following elements relating exclusively to the Products(2)in Europe:
     - intellectual property required for their commercialisation, and any related goodwill owned by AGI
        and its subsidiaries(3);
     - product registrations and marketing authorisations; and
     - the related inventory.
Aspen received an upfront cash consideration of EUR 263.2 million upon closure of the Transaction at the
end of November 2020. The second tranche of the purchase consideration, an amount of EUR 378.7 million,
was received on 25 June 2021.


(1) Excludes Russia and the other Commonwealth of Independent States countries.
(2) The brand names, and variations of the brand names, Arixtra, Fraxiparine, Mono-Embolex and Orgaran in Europe.
(3) Excluding certain goodwill relating to distribution of the Products in France.

Durban
1 July 2021

Sponsor
Investec Bank Limited
Date: 01-07-2021 04:19:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.

Share This Story